Clinical Trial Update: Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab (MK-3475) in microsatellite instability-high tumors (Cohort D) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microsatellite Instability-high Tumors

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: High Tumor Mutation Burden, High TMB (Tumor Mutation Burden) | Phase 2 | Status: COMPLETED | Results posted: 2023-05-19